FP
CARM

Flagship Pioneering’s Carisma Therapeutics CARM Stock Holding History

Flagship Pioneering’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-66,201
Closed -$2.91M – 6
2017
Q1 		$2.91M Hold
66,201
– – 0.77% 7
2016
Q4 		$2.53M Sell
66,201
-51,535
-44% -$2.27M 0.82% 7
2016
Q3 		$6.59M Buy
+117,736
New +$8.77M 1.8% 7

Other funds holding CARM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Flagship Pioneering's CARM Position: Q2 2017 in Review

Flagship Pioneering sold out of Carisma Therapeutics (CARM) in Q2 2017, closing a stake of 66,201 shares — an estimated $2.91M sold.

Flagship Pioneering first reported a position in CARM in Q3 2016 and held it in 3 quarters. The position peaked at $6.59M in Q3 2016. 26 funds tracked by Wall St. Rank hold CARM as of Q2 2017.

  • Flagship Pioneering reported no remaining Carisma Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Flagship Pioneering sold 66,201 Carisma Therapeutics shares in Q2 2017, an estimated $2.91M.
  • Flagship Pioneering first reported a position in Carisma Therapeutics in Q3 2016 and held it in 3 quarters.
  • Flagship Pioneering's Carisma Therapeutics position peaked at $6.59M in Q3 2016.
  • 26 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2017.

Based on Flagship Pioneering's 13F filing for Q2 2017, filed 2 Aug 2017.